FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
59.712,83 +785,66 (+1,33%)
Talis Biomedical Corporation (TLIS)
Dopo ore:
| Chiusura precedente | 8,89 |
| Aperto | 8,88 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 8,88 - 9,14 |
| Intervallo di 52 settimane | 4,35 - 9,32 |
| Volume | |
| Media Volume | 9.076 |
| Capitalizzazione | 16,653M |
| Beta (5 anni mensile) | 1,74 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -34,12 |
| Prossima data utili | 09 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireTalis Biomedical Announces Second Quarter 2023 Financial Results and Business Update
Conference call and webcast today at 4:30pm Eastern/1:30pm PacificREDWOOD CITY, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results for the second quarter ended June 30, 2023, and provided a business update. Recent Business Highlights Initiated clinical st
- GlobeNewswire
Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023
REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report second quarter 2023 financial results and provide a business update on Thursday, August 10, 2023, after market close. Company management will host a corresponding conference call beginnin
- GlobeNewswire
Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO)
REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care (POC), today announced that it has appointed Dr. Andrew A. Lukowiak as president and chief scientific officer, effective August 1, 2023. Dr. Lukowiak has more than 20 years of senior leadership experience in the clinical dia
